As a subsidiary for Mitsubishi Chemical Holdings Group, APIC manufactures APIs, intermediates, investigational new drugs, fine chemicals and reagents. This is the first facility that APIC has built outside of Japan.
Neuland spokeswoman Barbara Lindheim told us that the new facility will be dedicated to only APIC products and those for its customers.
“This plant is identical to other Neuland plants in terms of its technology and cGMP controls,” she told Outsourcing-pharma.com.
“It's different only due to the fact that the capacity is dedicated to producing products for APIC. We are not aware of other such plants being planned by APIC but it could be possible in the future.”
Pursuant to an agreement entered into in March 2013, Neuland constructed and will operate this and other manufacturing facilities dedicated to providing APIC with capacity for meeting the needs of its customers for pharmaceutical APIs and intermediates.
With customers located in 85 countries, Neuland also said it would push further into the Japanese market.
D.R. Rao, Chairman and Managing Director of Neuland Labs said, “This arrangement allows APIC to expand their business in Japan in a timely and cost-effective way, while also helping to raise Neuland’s profile as a quality supplier of APIs and intermediates to the Japanese market.”
Kiyoshi Kondo, President and CEO of APIC, added, “We welcome the inauguration of our dedicated Neuland manufacturing facility, a world-class operation that has come online just a year after our collaboration agreement was signed.
“This facility will benefit our growing customer base by rapidly increasing our capacity to deliver high quality, competitively-priced APIs and intermediates in partnership with Neuland, a company with a long history of outstanding quality and regulatory excellence.”